182 related articles for article (PubMed ID: 32583515)
1. Meta-analysis of the risk of autoimmune thyroiditis, Guillain-Barré syndrome, and inflammatory bowel disease following vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine.
Rosillon D; Willame C; Tavares Da Silva F; Guignard A; Caterina S; Welby S; Struyf F
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1159-1167. PubMed ID: 32583515
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus vaccines and Guillain-Barré syndrome: managing uncertainties.
Prescrire Int; 2016 Nov; 25(176):265-268. PubMed ID: 30715823
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
[TBL] [Abstract][Full Text] [Related]
4. Papillomavirus vaccination and Guillain-Barre Syndrome among girls: A cohort study in Spain.
Martín-Merino E; Castillo-Cano B; Martín-Perez M; Llorente-García A; Montero-Corominas D
Vaccine; 2021 Jul; 39(31):4306-4313. PubMed ID: 34175126
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L;
J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418
[TBL] [Abstract][Full Text] [Related]
6. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
[TBL] [Abstract][Full Text] [Related]
7. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England.
Andrews N; Stowe J; Miller E
Vaccine; 2017 Mar; 35(13):1729-1732. PubMed ID: 28245941
[TBL] [Abstract][Full Text] [Related]
8. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.
Grimaldi-Bensouda L; Rossignol M; Koné-Paut I; Krivitzky A; Lebrun-Frenay C; Clet J; Brassat D; Papeix C; Nicolino M; Benhamou PY; Fain O; Costedoat-Chalumeau N; Courcoux MF; Viallard JF; Godeau B; Papo T; Vermersch P; Bourgault-Villada I; Breart G; Abenhaim L;
J Autoimmun; 2017 May; 79():84-90. PubMed ID: 28190705
[TBL] [Abstract][Full Text] [Related]
9. Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.
Wang F; Wang D; Wang Y; Li C; Zheng Y; Guo Z; Liu P; Zhang Y; Wang W; Wang Y; Hou H
Front Immunol; 2022; 13():782198. PubMed ID: 35185881
[TBL] [Abstract][Full Text] [Related]
10. Risk of Guillain-Barré Syndrome following quadrivalent human papillomavirus vaccine in the Vaccine Safety Datalink.
Gee J; Sukumaran L; Weintraub E;
Vaccine; 2017 Oct; 35(43):5756-5758. PubMed ID: 28935469
[TBL] [Abstract][Full Text] [Related]
11. Estimation of mid-and long-term benefits and hypothetical risk of Guillain-Barre syndrome after human papillomavirus vaccination among boys in France: A simulation study.
Duong CH; Mueller JE; Tubert-Bitter P; Escolano S
Vaccine; 2022 Jan; 40(2):359-363. PubMed ID: 34865876
[TBL] [Abstract][Full Text] [Related]
12. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.
Ojha RP; Jackson BE; Tota JE; Offutt-Powell TN; Singh KP; Bae S
Hum Vaccin Immunother; 2014; 10(1):232-7. PubMed ID: 24013368
[TBL] [Abstract][Full Text] [Related]
13. Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine.
Deceuninck G; Sauvageau C; Gilca V; Boulianne N; De Serres G
Expert Rev Vaccines; 2018 Jan; 17(1):99-102. PubMed ID: 28972438
[TBL] [Abstract][Full Text] [Related]
14. Risk of Guillain-Barré syndrome after vaccination against human papillomavirus: a systematic review and meta-analysis, 1 January 2000 to 4 April 2020.
Boender TS; Bartmeyer B; Coole L; Wichmann O; Harder T
Euro Surveill; 2022 Jan; 27(4):. PubMed ID: 35086611
[TBL] [Abstract][Full Text] [Related]
15. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience.
Angelo MG; Zima J; Tavares Da Silva F; Baril L; Arellano F
Pharmacoepidemiol Drug Saf; 2014 May; 23(5):456-65. PubMed ID: 24644078
[TBL] [Abstract][Full Text] [Related]
16. Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries.
Arya DP; Said MA; Izurieta HS; Perez-Vilar S; Zinderman C; Wernecke M; Alexander M; White T; Su IH; Lufkin B; MaCurdy T; Kelman J; Forshee R
Vaccine; 2019 Oct; 37(43):6543-6549. PubMed ID: 31515146
[TBL] [Abstract][Full Text] [Related]
17. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HML; Lee BW; Rombo L; Tan NC; Rouzier R; De Simoni S; Suryakiran P; Hezareh M; Thomas F; Folschweiller N; Struyf F
Vaccine; 2018 Jan; 36(1):98-106. PubMed ID: 29174109
[TBL] [Abstract][Full Text] [Related]
18. Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain-Barré Syndrome and Narcolepsy.
Stowe J; Andrews N; Miller E
CNS Drugs; 2020 Jan; 34(1):1-8. PubMed ID: 31576507
[TBL] [Abstract][Full Text] [Related]
19. Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017-2018 season.
Perez-Vilar S; Wernecke M; Arya D; Lo AC; Lufkin B; Hu M; Chu S; MaCurdy TE; Kelman J; Forshee RA
Vaccine; 2019 Jun; 37(29):3856-3865. PubMed ID: 31122853
[TBL] [Abstract][Full Text] [Related]
20. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.
Willame C; Rosillon D; Zima J; Angelo MG; Stuurman AL; Vroling H; Boggon R; Bunge EM; Pladevall-Vila M; Baril L
Hum Vaccin Immunother; 2016 Nov; 12(11):2862-2871. PubMed ID: 27428517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
